EichorEICHOR
Condition: Stage Iii Hepatocellular Carcinoma Ajcc V7 Synced from ClinicalTrials.gov · August 07, 2026

Recruiting studies: Stage Iii Hepatocellular Carcinoma Ajcc V7

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metasta
Phase 1/Phase 2 · 4 location(s) · National Cancer Institute (NCI) · NCT06811116Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition Af
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT03942328Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT05269381Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma
Phase 2 · 1 location(s) · Mary Feng, MD · NCT04430452Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer
Phase 2 · 4 location(s) · Emory University · NCT07174570Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-
Phase 3 · 139 location(s) · NRG Oncology · NCT07166406Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The K
Phase 4 · 1 location(s) · OHSU Knight Cancer Institute · NCT07405086AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
Phase 1 · 2 location(s) · University of Southern California · NCT05791448Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel i
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT05092373Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04380545Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metast
Phase 2 · 16 location(s) · Academic and Community Cancer Research United · NCT05168163Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer
Phase 1/Phase 2 · 1 location(s) · Devalingam Mahalingam · NCT07042919
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.